Mon. Nov 28th, 2022

Fxtriangle | Market analysis | Managed trading

Fxtriangle will make Fx trading look easy.

Indian pharma market grows 2.4% YoY in Q1 after April-May slump

2 min read

The Indian pharma market has seen an encouraging pickup in total sales in June, but the pace of recovery is still slow. After a drop in April and May, the total pharma market grew about 2.4% year-on-year (y-o-y) in June.

The covid-19 pandemic that saw patient visits to doctors and hospitals decline during the lockdown is slowly reversing. But the overall growth rate still remains slow and could well slow down the rise of the Nifty Pharma index which gained about 27% year to date.

Volume growth is not yet of much comfort and fell about 11.8% y-o-y. While some of the fall was offset by price increases and new launches, the slowdown in patient inflow still remains a worry. Analysts say that the monsoon season could see a better growth in volumes, but normalcy is still some time away. A jump in covid-19 infections poses a threat to patient visits to hospitals and clinics. That’s evident in the slow growth in the anti-infectives and pain segment.

However, demand for chronic drugs and vitamins is encouraging. Chronic segment such as diabetes and cardio drugs continue to do well. Growth rates here have been positive, but marginally lower. Another thing to note is that generics as a segment has seen an improvement in sales, which suggests there is a higher demand.

But pharma companies could still offset the cost of lower sales since operating costs have also been low. “On the positive side, we expect Indian pharma companies to record lower travel, sales promotion and R&D expenses during the quarter. This is likely to lead to very modest or marginal decline in other expenses y-o-y. There is a possibility that the drop could trigger rationalization of costs going forward,” said Nomura India analysts in a client note.

Leave a Reply

Forex trading and any instruments related to Foreign Exchange Market are Speculative and carry substantial risk of loss of either partial equity or the entire deposit amount. Leverage adds up to the risk, before considering to invest in this venture, you should first consider your financial position and may seek the help of an independent financial advisor. FXtriangle dis-recommends the usage of loan instruments to trade in this market as it can hamper financial position. Please do not invest the money that you cannot afford to lose. FXtriangle provides all its services throughout the Globe Excluding (Nigeria, British Virgin Island & the Islamic Republic of Iran) and also provides limited service in some jurisdictions where investment in Overseas markets / Fx Exchanges are prohibited by Law If you are not sure to contact us before using any of our services. FXtriangle acts as an Independent Corporate Financial Advisor and connects you to various overseas exchanges and cannot be held liable for any financial damage occurring through their side. All of our partnered institutions are regulated in various jurisdictions.FXtriangle conducts an independent background check before partnering with any institutions to fulfill your investment objectives smoothly. The usage of our Business name, Logo or any trademark in any financial forum, website, review website, complaint arena, Billboards without our written permission will attract lawsuits.